In the News

 
Larry Kwak

Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.


CAR T Illuminated

City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.


robert w chen md 256x256

Clinical trial results in positive outcomes for patients with relapsed or treatment-resistant disease. Hodgkin lymphoma is typically considered to be one of the most curable forms of cancer, but some with the disease relapse or find that their cancer is resistant to treatment. For patients like this, a fully human monoclonal antibody called avelumab has shown promising results in a phase 1 clinical trial for safety and efficacy.


Presant-Cary

Here at ASCO 2017 in Chicago, we’ve been hearing about promising new clinical trials that have shown that immunotherapy can control some of the most resistant cancers.


Herrera-Alex

Alex F. Herrera, M.D., an assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, and a team of doctors at City of Hope and the Dana-Farber Cancer Institute examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose chemotherapy and underwent an autologous stem cell transplantation.


Chen-Robert

Everything changed when Hodgkin lymphoma patient Lowell Winer joined a Phase II clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.